KB Home Announces the Grand Opening of Its Newest Community in Desirable Orting, Washington
What sets KB Home apart is the company's focus on building strong, personal relationships with every customer, so they have a real partner in the homebuying process. Every KB home is uniquely built for each customer, so no two KB homes are the same. Homebuyers have the ability to personalize their new home, from floor plans to exterior styles to where they live in the community. Their home comes to life in the KB Home Design Studio, a one-of-a-kind experience where customers get both expert advice and the opportunity to select from a wide range of design choices that fit their style and their budget. Reflecting the company's commitment to creating an exceptional homebuying experience, KB Home is the #1 customer-ranked national homebuilder based on homebuyer satisfaction surveys from a leading third-party review site.
'We are pleased to offer homebuyers in the Seattle-Tacoma area spacious new two-story homes in the charming and scenic town of Orting,' said Ryan Kemp, President of KB Home's Seattle division. 'Bridgewater is situated on the banks of the Puyallup River, which features opportunities for bird-watching, fishing, kayaking, tubing and rafting. Homeowners will appreciate the stunning views of Mount Rainier and the Cascade foothills as well as the proximity to schools and family friendly parks, including Calistoga and Whitehawk Parks. At KB Home, we're here to help you achieve your dream with a personalized new home built uniquely for you and your life.'
Innovative design plays an essential role in every home KB builds. The company's floor plans inspire contemporary living, with a focus on roomy, light-filled spaces that have easy indoor/outdoor flow. KB homes are engineered to be highly energy and water efficient and include features that support healthier indoor environments. They are also designed to be ENERGY STAR ® certified — a standard that fewer than 12% of new homes nationwide meet — offering greater comfort, well-being and utility cost savings than new homes without certification.
Bridgewater is in a ideal location that offers homebuyers an exceptional lifestyle. The community is situated at the corner of Calistoga Way West and Chief Emmons Lane Northwest, providing easy access to Highways 167, 410 and 512, Interstate 5, downtown Tacoma, Seattle-Tacoma International Airport and the area's major employment centers. Bridgewater is close to shopping and dining at Orting's Pioneer Village Shopping Center. The new neighborhood is also near Foothills Trail, which offers walking, biking, running and horseback riding, and a short drive to Crystal Mountain Resort, White Pass and Mount Rainier National Park, which features hiking, biking, skiing and snowboarding.
The Bridgewater sales office and model home are open for walk-in visits and private in-person tours by appointment. Homebuyers also have the flexibility to arrange a live video tour with a sales counselor. Pricing begins from the low $500,000s.
For more information on KB Home, call 888-KB-HOMES or visit kbhome.com.
About KB Home
KB Home is one of the largest and most trusted homebuilders in the United States. We operate in 49 markets, have built nearly 700,000 quality homes in our more than 65-year history, and are honored to be the #1 customer-ranked national homebuilder based on third-party buyer surveys. What sets KB Home apart is building strong, personal relationships with every customer and creating an exceptional experience that offers our homebuyers the ability to personalize their home based on what they value at a price they can afford. As the industry leader in sustainability, KB Home has achieved one of the highest residential energy-efficiency ratings and delivered more ENERGY STAR ® certified homes than any other builder, helping to lower the total cost of homeownership. For more information, visit kbhome.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Currax Expands Access to FDA-Approved Obesity Treatment with Brand Name Contrave® with New Cash Price Available via GoodRx
New cash pay program offers Contrave, the #1 branded oral non-GLP-1 weight loss medication brand, for as low as $199 per month* BRENTWOOD, Tenn., July 15, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty biopharmaceutical company and manufacturer of the #1 branded oral non-GLP-1 weight loss medication brand CONTRAVE® (naltrexone HCl/bupropion HCl), announces today the launch of its latest cost saving initiative with GoodRx, the leading platform for medication savings in the U.S. The national access program introduces a cash pay prescription offer for Contrave, expanding access to affordable weight management medication for more patients, regardless of insurance. According to the CDC, more than 40% of U.S. adults are living with obesity, yet cost and coverage barriers often limit access to effective treatment options. Now, patients can access Contrave at a cash price of $199 via GoodRx, regardless of insurance status, allowing them to fill their Contrave prescription at over 70,000 pharmacies across the United States. Through the program, millions of U.S. adults living with obesity and weight-related health issues will have access to obesity treatment. "At Currax, we truly believe in access for all and putting patients at the center of everything we do," said George Hampton, CEO of Currax Pharmaceuticals. "By making our cash price available through GoodRx, we are continuing to reduce barriers and provide an easy path for patients to get the treatment they need to manage their weight and improve their overall health." Obesity is one of the most pressing health challenges in the U.S., yet many people still struggle to access effective treatment. By combining Currax's clinical leadership in obesity care with GoodRx's reach and reputation for affordability, this collaboration removes a major barrier for patients who may not otherwise have access to FDA-approved medications. Together, the two companies are helping more people take control of their health with greater confidence and fewer hurdles. "Though millions of Americans struggle with obesity, weight management medications can be cost-prohibitive—with or without insurance—causing many people to delay or abandon prescribed treatments. These types of access and affordability challenges are why many pharmaceutical companies partner with GoodRx to reduce friction," said Dorothy Gemmell, Chief Commercial Officer at GoodRx. "By working with Currax to help consumers save money on Contrave, we're helping close this gap and delivering a simple affordability solution that improves access to a life-changing medication." Contrave is an FDA-approved, prescription-only oral medication for adults with obesity or those who are overweight with weight-related medical problems, used as an adjunct to a reduced-calorie diet and increased physical activity. For more information or to access the GoodRx Contrave savings card, visit: *Program benefit maximums and eligibility restrictions may apply. About CurraxCurrax Pharmaceuticals LLC is a specialty pharmaceutical business focused on addressing the #1 and #2 causes of preventable death in the United States, smoking and obesity. Currax distributes a range of both branded and generic pharmaceutical products, including CONTRAVE® (naltrexone HCl/bupropion HCl), ONZETRA® Xsail® (sumatriptan nasal powder), Silenor® (doxepin), Treximet®, (sumatriptan/naproxen sodium), and the authorized generic of Treximet®. For more information, please visit About CONTRAVE: CONTRAVE®, is an extended-release fixed dose combination of naltrexone and bupropion (naltrexone HCL/bupropion HCL) indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes. For full Prescribing Information, including BOXED Warning and Medication Guide, please go to Media Contactcurrax@ View original content to download multimedia: SOURCE Currax Pharmaceuticals LLC Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
29 minutes ago
- Yahoo
Conagra Brands, Inc. (CAG) Had To 'Eat' The Tariff, Says Jim Cramer
We recently published . Conagra Brands, Inc. (NYSE:CAG) is one of the stocks Jim Cramer recently discussed. Conagra Brands, Inc. (NYSE:CAG) is a food products company, which, like its peers, has struggled on the stock market in 2025. The firm's shares have lost close to 30% in 2025 and are down by 10% over the past month. Conagra Brands, Inc. (NYSE:CAG)'s latest share price dip came in July after the stock fell by 4.4% after the firm's fiscal fourth quarter earnings report. The result saw it miss analyst EPS and revenue estimates of $0.58 and $2.83 billion by posting $0.56 and $2.78 billion. Conagra Brands, Inc. (NYSE:CAG) also missed analyst fiscal 2026 guidance by a wide margin as its midpoint EPS of $1.775 was nowhere close to the $2.18 analysts had penciled in. The miss was due to tariffs, and here's what Cramer said: 'Overlooked was the Conagra, which does not have great brands historically had to eat the tariff on tin cans and their inflation rate's gonna be 7% and that's why that stock got so many different price target cuts. A worker assembling a meal in a food production facility. Previously, Cramer mentioned that Conagra Brands, Inc. (NYSE:CAG) was removing dyes from its products: 'Conagra, and . . . Nestle, are all taking the dyes out. The synthetic dyes.' While we acknowledge the potential of CAG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
29 minutes ago
- Yahoo
Levi Strauss & Co. (LEVI): CEO Is 'Doing A Great Job,' Says Jim Cramer
We recently published . Levi Strauss & Co. (NYSE:LEVI) is one of the stocks Jim Cramer recently discussed. Levi Strauss & Co. (NYSE:LEVI) is one of the most well-known apparel companies in America. Its shares have gained 26% year-to-date, helped by an 11% jump in July. Levi Strauss & Co. (NYSE:LEVI)'s stock soared after the firm's fiscal second quarter earnings report saw it guide 1.5% midpoint 2025 revenue growth, which was higher than the 1.5% drop that the firm had forecast earlier. Cramer's previous remarks about the firm praised it before the earnings report was released. Here's what he said on Friday: 'Look we saw it last night, Michelle Gass told me at Levi, look we're gonna be able to overcome it cause they have, they can take price cause Levi's is a great brand. A stylishly dressed man wearing jeans and a jacket from the company, smiling confidently. This wasn't the first time Cramer had praised Gass. Back in April, he commented: 'She's trying to figure out what to do where. But what matters is they have tremendous organic growth. Management reiterated their earnings per share guidance of $1.20, $1.25. Our friend Matt Boss has a terrific piece out saying it's the early innings. Upgrades to overweight. Don't forget they have a 3.8% yield. And denim is doing incredibly well. And you come into stocks at 10 times earnings. This is the kind of thing that I like. Stock that is just being crushed where the fundamentals are actually improving. And there are enough out there that you just have to find them. So I like Levi Strauss very much. And look, I think that their direct-to-consumer initiative is very strong.' While we acknowledge the potential of LEVI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
